|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
78.65 USD |
-0.69% |
|
-4.45% | -4.11% |
Published on 02/09/2026
at 10:04 am EST
MT Newswires
© MT Newswires –
2026
| 02:21am |
GE Healthcare Technologies Inc. Declares Cash Dividend for the First Quarter of 2026, Payable on May 15, 2026 |
CI |
Feb. 09 |
GE Healthcare Launches ReadyFix Fleet Management Solution to Help Enhance Operational Efficiency and Reliable Patient Care |
CI |
Feb. 09 |
GE Healthcare launches Readyfix fleet management solution |
RE |
Feb. 09 |
GE HealthCare Launches ReadyFix Remote Device Management in US |
MT |
Feb. 06 |
Rothschild & Co Redburn Adjusts Price Target on GE Healthcare Technologies to $110 From $108, Maintains Buy Rating |
MT |
Feb. 06 |
BNP Paribas Adjusts Price Target on GE Healthcare Technologies to $95 From $92, Maintains Outperform Rating |
MT |
Feb. 05 |
GE Healthcare announced a collaboration with Diagnoly to advance the use of artificial intelligence in fetal ultrasound assessments |
RE |
Feb. 05 |
Barclays Adjusts Price Target on GE Healthcare Technologies to $87 From $86, Maintains Equalweight Rating |
MT |
Feb. 05 |
Evercore ISI Adjusts Price Target on GE Healthcare Technologies to $98 From $95, Maintains Outperform Rating |
MT |
Feb. 05 |
Piper Sandler Adjusts Price Target on GE Healthcare Technologies to $96 From $94, Maintains Overweight Rating |
MT |
Feb. 05 |
Wells Fargo Adjusts Price Target on GE Healthcare Technologies to $97 From $95, Maintains Overweight Rating |
MT |
Feb. 05 |
Goldman Sachs Adjusts GE Healthcare Technologies PT to $97 From $98, Maintains Buy Rating |
MT |
Feb. 05 |
Stifel Nicolaus Adjusts GE Healthcare Technologies PT to $98 From $95, Maintains Buy Rating |
MT |
Feb. 04 |
BTIG Research Adjusts GE Healthcare Technologies PT to $91 From $87, Maintains Buy Rating |
MT |
Feb. 04 |
Tranche Update on GE HealthCare Technologies Inc.’s Equity Buyback Plan announced on April 30, 2025. |
CI |
Feb. 04 |
GE HealthCare Technologies Inc., Q4 2025 Earnings Call, Feb 04, 2026 |
|
Feb. 04 |
Wall Street: When AI Stops Being a Buzzword and Starts Being a Threat |
 |
Feb. 04 |
GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices |
RE |
Feb. 04 |
GE HealthCare Technologies Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 |
CI |
Feb. 04 |
GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices |
RE |
Feb. 04 |
GE Healthcare Q4 Adjusted Earnings Fall, Revenue Rises; 2026 Outlook Set — Shares Up Pre-Bell |
MT |
Feb. 04 |
(GEHC) GE Healthcare Technologies Expects Full Year 2026 Adjusted EPS Range $4.95 – $5.15, vs. FactSet Est of $4.94 |
MT |
Feb. 04 |
Earnings Flash (GEHC) GE HealthCare Technologies Inc. Reports Q4 Revenue $5.70B, vs. FactSet Est of $5.61B |
MT |
Feb. 04 |
Earnings Flash (GEHC) GE HealthCare Technologies Inc. Posts Q4 Adjusted EPS $1.44 per Share, vs. FactSet Est of $1.40 |
MT |
Feb. 02 |
GE HealthCare Announces U.S. FDA 510(k) Clearance and CE Mark for Allia Moveo and marks First Global Installation, Advancing Precision Care in the Interventional Suite |
CI |
GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. The Company provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.
Trader
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Buy
Average target price
93.25USD
Spread / Average Target
+18.56%
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
link